Hepadnaviridae infectious disease

This study tests a new two-drug combination (ASC22 and Peg-IFNa) to see if it can functionally cure chronic hepatitis B. About 150 adults with low virus levels will receive the treatment. The goal is to raise the cure rate above 50% without needing lifelong medication.

This early-stage trial tests a new vaccine called WGc0201 in 9 adults with chronic hepatitis B who are already on standard antiviral therapy. The vaccine is designed to boost the immune system to clear the virus, potentially leading to a functional cure. The main goal is to check…

This early-stage study tests a new drug called IB-001 for chronic hepatitis B. It will first check safety in up to 60 healthy volunteers, then test multiple doses in about 30 people with chronic hepatitis B. The main goal is to see if the drug is safe and how the body handles it.

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all ne…

This early-stage trial is testing an experimental drug called GIGA-2339 in 48 adults with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either GIGA-2339 or a placebo by IV infusion, and researchers will…

This study tests a new biologic drug called HH-006 in 45 adults with chronic hepatitis B. Participants receive injections for 48 weeks, and researchers track how well the drug lowers hepatitis B surface antigen (HBsAg) levels. The goal is to see if the drug can control the infect…

This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The m…

This study tests a therapeutic vaccine called TherVacB in 81 adults with chronic hepatitis B who are already on antiviral medication. The vaccine is given as a series of shots to boost the immune system and lower hepatitis B virus levels. The main goals are to check safety and se…

This early-stage study tests an injection called AHB-171 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it shows any signs of controlling the virus. About 110 participants will be enrolle…

This Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…

This study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …

This early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…

This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the …

This study compares two antiviral drugs, tenofovir alafenamide (TAF) and entecavir, in 140 adults with chronic hepatitis B. The goal is to see which one controls the virus better and causes fewer kidney problems. Participants take one pill daily for about a year.

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After 3 months, researchers will compare how wel…

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves witho…

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetec…

This Phase 2 study tests an experimental drug called ALG-000184 against a standard hepatitis B medication (tenofovir) in 200 adults with chronic hepatitis B. Participants take one pill daily for 48 weeks. The main goal is to see if the new drug can lower hepatitis B virus levels …

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…

This early-stage study is testing whether stem cells from donated umbilical cords are safe and can help people with liver damage from hepatitis B. About 20 adults with moderate to severe cirrhosis will receive the stem cell treatment. The main goal is to see if it improves liver …

This study tests whether using early drug monitoring and a dose-adjustment calculator can help infants under 90 days old with sepsis reach target vancomycin levels more quickly. Currently, doctors must wait 24-48 hours to check drug levels, which can delay effective treatment. Th…

This study involves over 16,000 people with chronic hepatitis B across three hospitals. The goal is to increase the number of patients referred to liver specialists and started on antiviral treatment. Researchers will also track how antiviral therapy affects patients' quality of …

This study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

This 5-year study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications in people with chronic hepatitis B and diabetes who already have early liver scarring. 412 participants will receive either dapagliflozin or a placebo daily. The goal is to see…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This study compares two ways of giving the antibiotic cefepime to very sick patients with sepsis in the ICU. The new method adjusts the dose based on the patient's kidney function, using only standard doses. The main goal is to see if this approach is easy for doctors to use and …

This study tests a single dose of a new antibody (HepB mAb19) in 37 adults with chronic hepatitis B who are already on standard antiviral pills. The main goal is to see if the antibody is safe and how long it stays in the body. It is an early-phase trial, so it focuses on safety …

This Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental dru…

This study tests whether hepatitis B immunoglobulin (HBIG) can help people with chronic hepatitis B stay virus-free after they've cleared the surface antigen (a key sign of cure). Researchers will give HBIG shots to 132 participants who already cleared the virus with standard the…

This early-stage study tests the safety of a new drug, Tune-401, in 36 adults with chronic hepatitis B. Participants must already be on standard antiviral medication. The goal is to see if Tune-401 is safe and how the body processes it, not yet to cure the infection.

This phase 3 study tests azvudine tablets in 120 people with chronic hepatitis B. The drug works by both fighting the virus and activating the immune system. Researchers will monitor viral load, liver function, and immune activity over 12 months to see if azvudine can help achiev…

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether giving zinc supplements along with standard antibiotics can reduce deaths and improve recovery in young infants (0-59 days old) hospitalized with severe infections like sepsis or pneumonia. About 3,250 babies in Tanzania will receive either zinc or a plac…

This early-stage study tests a new medicine called SA1211 for chronic hepatitis B, a long-term liver infection. Researchers will check safety and how the body processes the drug in 80 healthy volunteers and people with hepatitis B. The goal is to see if it can help control the vi…

This study looks at whether taking a specific gut bacterium (Bacteroides fragilis) along with branched-chain amino acids can help clear the hepatitis B virus in people with chronic infection. About 40 participants will receive this combo as an add-on to their usual antiviral trea…

This study tests an experimental drug called HRS-5635, given alone or with other medications, in people with chronic hepatitis B. The goal is to lower or clear the hepatitis B surface antigen (HBsAg) from the blood, which could mean better long-term control of the virus. About 36…

This Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at …

This study tests whether lungs from donors with hepatitis B can be safely given to people who do not have hepatitis B. The donated lungs are treated with UV light during a special preservation process, and recipients receive antiviral drugs and antibodies to prevent infection. Tw…

This early study is testing whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe for people who already have chronic hepatitis B. Ten adults on stable antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses ov…

This study tests a new medicine, LW231, in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, others will get it together with standard antiviral pills. The trial involves about…

This early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…

This phase 2 trial tests a combination of an anti-PD-1 antibody, interferon, and standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to boost the immune system to clear the virus and achieve a functional cure, where the virus stays under control without l…

This pilot study tests a drug called Imdusiran (AB-729) in 10 people with chronic hepatitis B. Participants receive four injections over 24 weeks and undergo two liver biopsies to measure how the drug works inside the liver and how it affects the virus. The goal is to understand …

This phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The …

This study is testing a drug called TAF (tenofovir alafenamide) in pregnant women with chronic hepatitis B. The goal is to see if taking TAF daily from week 28-32 of pregnancy until delivery can prevent the baby from catching the virus. Researchers will also check how the drug mo…

This study is testing a new rapid diagnostic device called TruPlex that can detect HIV, Hepatitis B, and Syphilis from a small blood sample. Researchers will enroll 1000 adults at risk for these infections to see how accurate and easy the test is to use in clinics and point-of-ca…

This study looks at whether magnetic resonance elastography (MRE), a special type of MRI, can accurately measure liver scarring (fibrosis) in people with chronic hepatitis B. Researchers will compare MRE results to standard liver biopsies in 600 adults. If MRE works well, it coul…

This study aims to see if a dried blood spot test can effectively screen drug users for hepatitis B, hepatitis C, and AIDS. Researchers will enroll 500 former or active drug users. The goal is to find a simpler way to detect these infections in a hard-to-reach population.

This study is testing a new medical device called MagIA IBC that uses a single drop of blood from a finger prick to screen for HIV, hepatitis B, and hepatitis C at the same time. Researchers will enroll 252 adults who are known or suspected to have one of these infections. The go…

This study tests a new device called MagIA H3S that can screen for HIV, hepatitis B, hepatitis C, and syphilis using a single blood sample. Researchers will enroll about 2,950 people in Ivory Coast and Kenya to see how accurate the device is compared to standard lab tests. If it …

This phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…

This early-phase study tests whether anakinra, a drug that blocks inflammation, can make the heart more sensitive to inotropes (medicines that strengthen heart contractions) in people with end-stage heart failure. If successful, patients might need lower, safer doses of inotropes…

This study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…

This study looks at how the immune system changes with age and how that affects the risk of infections in people 60 and older. Researchers will collect blood, urine, stool, and other samples from elderly patients with infections and healthy older adults. By analyzing immune cells…

This study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…

This study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…

This study aims to improve how doctors evaluate and manage people who have been exposed to bioterrorism agents (like anthrax) or emerging infectious diseases (like SARS or new flu strains). Up to 200 participants, including patients and healthcare workers, will be monitored and t…

This study is creating a large collection of blood samples and health data from 3500 people with hepatitis B, including those who have already cleared the virus. Researchers will use these samples to look for viral RNA patterns that could signal a functional cure. No new treatmen…

This study will follow 10,000 people in Australia who have chronic hepatitis B to see how well they are connected to care and treatment. Researchers will collect information from clinics across the country to understand who is getting treated and what their health needs are. No n…

This study looks at genetic changes in natural killer (NK) and B cells—key immune cells—in people with chronic hepatitis B. Researchers want to understand why these cells don't work properly during long-term infection. The study will analyze blood samples from 140 adults with chr…

This study follows 390 adults in Zambia with hepatitis B, some also with HIV, to see how their liver and immune system change over time. Participants join when diagnosed or starting standard antiviral treatment and are monitored for years. The goal is to learn more about the dise…

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable levels in other body fluids like saliva or semen. Researchers will compare treated patients with suppressed virus to untreated patients with active…

This study looks at how the hepatitis B vaccine triggers T cells, a key part of the immune system. Researchers will test blood from 115 healthy adults 5 to 10 weeks after vaccination to see if they have T cells that recognize the hepatitis B virus. The goal is to understand why s…

This study looks at why the hepatitis B virus (HBV) stays in the liver for so long, even with treatment. Researchers will use a gentle needle technique to take small liver samples from 100 adults with chronic HBV. They want to see how the virus and the immune system interact insi…

This study tests a new, lightweight ultrasound device called NeoDoppler that can be gently placed on a newborn's soft spot (fontanelle) to continuously measure blood flow in the brain. Researchers will enroll 180 preterm and full-term infants, including those with conditions like…

This study aims to understand how liver diseases like fatty liver, hepatitis B, fibrosis, and cirrhosis develop by analyzing individual liver cells and their spatial organization. Researchers will collect blood and discarded liver tissue from 240 patients undergoing surgery or bi…

This study is looking at whether early signs of inflammation in the blood can help identify which patients with infections are at risk for serious complications like sepsis. Researchers will follow 4,200 adults with confirmed or suspected infections, as well as healthy controls, …

This study follows 490 adults with a past hepatitis B infection who need immune-suppressing treatments. Researchers will monitor bone, kidney, and metabolic health over 4 years to understand the long-term side effects of antiviral drugs. The goal is to create better safety guidel…

This study looks at immune cells from lymph nodes, tonsils, and liver tissue of people with chronic hepatitis B. Researchers want to understand how the germinal centers—the parts of the body that train immune cells—respond to the virus. By analyzing these tissues, they hope to le…

This study looks at how common certain infections are among 250 asylum seekers living in reception centers in Italy. Participants must be adults who arrived in Italy between 2 and 36 months ago. The goal is to better understand infection rates to improve health screening and care…

This study looks at the link between gum (periodontal) disease and hepatitis B+D infection, and whether the drug bulevirtide changes that relationship. Researchers will measure inflammation markers in saliva and gum fluid from 25 adults: those with hepatitis B+D on bulevirtide, t…

This study follows 3,000 adults with cirrhosis or who have had a liver transplant at a French hospital. Researchers will track survival and complications like bleeding or infections to learn how to improve patient care. The goal is to collect data and samples to better understand…

This study looks at how the antibiotic ceftazidime avibactam behaves in 30 children with severe infections who are in intensive care, some on life support. Researchers will measure drug levels in the blood to understand the right dose. The goal is to improve treatment for life-th…

This early study tests a single dose of the drug pevifoscorvir in 30 people with chronic hepatitis B, some with kidney problems and some with healthy kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to learn how to dose the drug pro…

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This study looks at how the antifungal medicine caspofungin behaves in children with severe infections, especially those with liver problems or on life support like ECMO. Researchers will measure drug levels in the blood to understand dosing needs. About 60 children in intensive …

This study will collect data from 2,000 children admitted to pediatric intensive care units (PICUs) with severe infections across major Chinese cities. Over 10 years, researchers will track which germs cause these infections, how they are treated, and patient outcomes. The goal i…

This study looks at two common antibiotic combinations given to hospitalized adults with infections: vancomycin plus piperacillin-tazobactam, or vancomycin plus cefepime. The goal is to see if one is less likely to cause kidney injury than the other, using more sensitive markers …

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This early-stage study tests a single dose of the drug pevifoscorvir sodium in 16 adults: 8 with moderate liver impairment and 8 healthy volunteers. Researchers want to see how the drug is processed in the body and if it is safe. The goal is to gather information for future dosin…

This study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses …

This observational study aims to develop a rapid T-cell test to help manage patients with chronic hepatitis B (HBV) and hepatitis B/D (HBV/HDV) co-infection. Researchers will analyze immune responses in 300 adult patients to understand how T-cells react to the viruses. The goal i…

This study aims to find out how many people with hepatitis B also have hepatitis delta, a more serious liver infection. Researchers will test 244 adults in hospitals, addiction clinics, and prisons in Bergamo, Italy. The goal is to improve detection and understand the true burden…

This study looks at DNA methylation patterns in 100 people with severe liver failure caused by hepatitis B. Researchers aim to build a model that predicts how the disease will progress, which could help doctors make better treatment decisions. The study is observational and does …

This pilot study is testing whether a smart wristband can accurately measure drug levels in sweat compared to standard blood tests. Researchers will collect sweat, saliva, and blood samples from 100 patients with chronic or infectious diseases who are taking medications like cycl…

This study follows 33,000 adults with chronic hepatitis B to see how well different antiviral medicines work over up to 5 years. Researchers will compare treatments like entecavir, tenofovir, and peginterferon to find which ones best prevent liver cancer and other serious liver p…

This study is looking for new ways to diagnose sepsis, a life-threatening reaction to infection, earlier in the emergency room. Researchers will study the immune responses of 3,300 adults with suspected infections to find patterns that signal sepsis. The goal is to improve diagno…

This study will follow 5000 people with chronic hepatitis B who are not on antiviral treatment, aged 1 to 80, for several years. Researchers will take blood samples every six months to track how the immune system responds to the virus as patients age. The goal is to better unders…

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…

This real-world study is following 15,000 people with chronic hepatitis B across 200 hospitals in China. Researchers are comparing how well different antiviral drugs and interferon injections work to prevent liver cancer and improve long-term health. The goal is to find the best …